last update more than 15 m growth in GP in PP , more than 30 m GP in Branded products and 1.2 m growth in international , reduction in OPEX in both dermatology and PP and increase in OPEX in branded products for a bigger market share , directing cost to priority women health products to have a bigger market share across 50 us states to have a share in 5 billion contraceptive sale across usa and give women more coc option and become a destination in women health and the go to with all prescribers considering mayne pharma products
Refocused business delivering improved momentum and positive contribution in 2H
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.05 |
Change
0.040(0.80%) |
Mkt cap ! $410.2M | |||
| Open | High | Low | Value | Volume |
| $5.02 | $5.08 | $4.97 | $1.369M | 273.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1151 | $5.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.09 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |